$24.22
0.74% today
Nasdaq, Sep 30, 04:49 pm CET
ISIN
US1523091007
Symbol
CNTA

Centessa Pharmaceuticals plc - ADR Target price 2025 - Analyst rating & recommendation

Centessa Pharmaceuticals plc - ADR Classifications & Recommendation:

Buy
94%
Hold
6%

Centessa Pharmaceuticals plc - ADR Price Target

Target Price $33.66
Price $24.40
Potential
Number of Estimates 15
15 Analysts have issued a price target Centessa Pharmaceuticals plc - ADR 2026 . The average Centessa Pharmaceuticals plc - ADR target price is $33.66. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 17 Analysts recommend Centessa Pharmaceuticals plc - ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Centessa Pharmaceuticals plc - ADR stock has an average upside potential 2026 of . Most analysts recommend the Centessa Pharmaceuticals plc - ADR stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.00 15.30
100.00%

15 Analysts have issued a sales forecast Centessa Pharmaceuticals plc - ADR 2025 . The average Centessa Pharmaceuticals plc - ADR sales estimate is

$15.3m
Unlock
. This is
2.00% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$15.8m 5.00%
Unlock
, the lowest is
$14.7m 2.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $0.0 100.00%
2026
$0.0 100.00%
Unlock
2029
$423m 199.60%
Unlock
2030
$762m 80.35%
Unlock
2031
$1.2b 50.98%
Unlock
2032
$1.5b 30.41%
Unlock

4 Analysts have issued an Centessa Pharmaceuticals plc - ADR EBITDA forecast 2025. The average Centessa Pharmaceuticals plc - ADR EBITDA estimate is

$-214m
Unlock
. This is
10.50% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-211m 11.97%
Unlock
, the lowest is
$-215m 10.17%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-200m 17.39%
2025
$-214m 6.99%
Unlock
2026
$-269m 25.85%
Unlock
2027
$-312m 15.63%
Unlock

EBITDA Margin

16 Centessa Pharmaceuticals plc - ADR Analysts have issued a net profit forecast 2025. The average Centessa Pharmaceuticals plc - ADR net profit estimate is

$-189m
Unlock
. This is
18.12% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-169m 26.90%
Unlock
, the lowest is
$-197m 14.71%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-236m 56.04%
2025
$-189m 19.84%
Unlock
2026
$-224m 18.41%
Unlock
2027
$-239m 6.70%
Unlock
2028
$-72.4m 69.68%
Unlock
2029
$118m 263.21%
Unlock
2030
$300m 154.33%
Unlock
2031
$562m 86.97%
Unlock
2032
$773m 37.60%
Unlock

Net Margin

2029
27.95% 154.47%
Unlock
2030
39.42% 41.04%
Unlock
2031
48.81% 23.82%
Unlock
2032
51.50% 5.51%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.06 -1.41
31.21% 31.55%
P/E negative
EV/Sales 194.36

16 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast for earnings per share. The average Centessa Pharmaceuticals plc - ADR EPS is

$-1.41
Unlock
. This is
18.02% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.26 26.74%
Unlock
, the lowest is
$-1.47 14.53%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.06 31.21%
2025
$-1.41 31.55%
Unlock
2026
$-1.67 18.44%
Unlock
2027
$-1.78 6.59%
Unlock
2028
$-0.54 69.66%
Unlock
2029
$0.88 262.96%
Unlock
2030
$2.24 154.55%
Unlock
2031
$4.20 87.50%
Unlock
2032
$5.77 37.38%
Unlock

P/E ratio

Current -14.19 28.47%
2025
-17.29 21.88%
Unlock
2026
-14.60 15.56%
Unlock
2027
-13.68 6.30%
Unlock
2028
-45.14 229.97%
Unlock
2029
27.65 161.25%
Unlock
2030
10.87 60.69%
Unlock
2031
5.82 46.46%
Unlock
2032
4.23 27.32%
Unlock

Based on analysts' sales estimates for 2025, the Centessa Pharmaceuticals plc - ADR stock is valued at an EV/Sales of

194.36
Unlock
and an P/S ratio of
203.58
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 198.24 24.96%
2025
194.36 1.96%
Unlock
2029
7.03 66.62%
Unlock
2030
3.90 44.55%
Unlock
2031
2.58 33.77%
Unlock
2032
1.98 23.32%
Unlock

P/S ratio

Current 207.66 29.86%
2025
203.58 1.96%
Unlock
2029
7.37 66.62%
Unlock
2030
4.09 44.55%
Unlock
2031
2.71 33.77%
Unlock
2032
2.08 23.32%
Unlock

Current Centessa Pharmaceuticals plc - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
Locked
Locked Sep 03 2025
Chardan Capital
Locked
Locked
Locked Aug 12 2025
Chardan Capital
Locked
Locked
Locked Jul 30 2025
Truist Securities
Locked
Locked
Locked Jul 21 2025
Needham
Locked
Locked
Locked May 28 2025
Chardan Capital
Locked
Locked
Locked May 08 2025
Piper Sandler
Locked
Locked
Locked Mar 31 2025
Analyst Rating Date
Locked
Wells Fargo:
Locked
Locked
Sep 03 2025
Locked
Chardan Capital:
Locked
Locked
Aug 12 2025
Locked
Chardan Capital:
Locked
Locked
Jul 30 2025
Locked
Truist Securities:
Locked
Locked
Jul 21 2025
Locked
Needham:
Locked
Locked
May 28 2025
Locked
Chardan Capital:
Locked
Locked
May 08 2025
Locked
Piper Sandler:
Locked
Locked
Mar 31 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today